Onkologie. 2016:10(2):66-71 | DOI: 10.36290/xon.2016.016

Primary cutaneous lymphomas: current view of rare hematologic malignancies

Jindřich Polívka
I. interní klinika Všeobecná fakultní nemocnice a 1. Lékařská fakulta Univerzity Karlovy v Praze

Primary cutaneous lymphomas are rare and heterogenous group of lymphoproliferative disorders involving the skin. The diagnosis

of primary cutanous lymphomas require the intergration of clinical and histopathologic data. Treatment depends on the subtype

of cutaneous lymphoma and clinical stage of the disease. Treatment requires a multidisciplinary approach. Review article aims

to present the current view of the diagnostic and therapeutic approach to primary cutaneous lymphomas, is more focused on

mycosis fungoides and Sézary syndrome.

Keywords: cutaneous lymphomas, mycosis fungoides, Sézary syndrome

Published: May 1, 2016  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Polívka J. Primary cutaneous lymphomas: current view of rare hematologic malignancies. Onkologie. 2016;10(2):66-71. doi: 10.36290/xon.2016.016.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. Willemze R, Jaffe E, Burg G, et al. WHO-EORTC classification for cutaneous lymphomas. Blood 2005; 105: 3768-3785. Go to original source... Go to PubMed...
    2. Swerdlow SH, Campo E, Harris NL, et al. WHO classification of tumours of haematopoietic and lymphoid tissue. 4th edition. Lyon (France): IARC Press; 2008.
    3. Korgavkar K, Xiong M, Weinstock M. Changing incidence trends of cutaneous T-cell lymphoma. JAMA Dermatol 2013; 149(11): 1295-1299. Go to original source... Go to PubMed...
    4. Bradford PT, Devesa SS, Anderson WF, et al. Cutaneous lymphoma incidence patterns in the United States: a population-based study of 3884 cases. Blood 2009; 113: 5064-5073. Go to original source... Go to PubMed...
    5. Lima M. Cutaneous primary B-cell lymphomas: from diagnosis to treatment. An Bras Dermatol 2015; 90(5): 687-706. Go to original source... Go to PubMed...
    6. Olsen EA. Evaluation, Diagnosis, and Staging of cutaneous Lymphoma. Dermatol Clin 2015; 33: 643-654. Go to original source... Go to PubMed...
    7. Pimpinelli N, Olsen EA, Santucci M, et al. Defining early mycosis fungoides. J Am Acad Dermatol 2005; 53: 1053-1063. Go to original source... Go to PubMed...
    8. Kim YH, Willemze R, Pimpinelli N, et al. TNM classification system for primary cutaneous lymphomas other than mycosis fungoides and Sézary syndrome: a proposal of the International Society for Cutaneous Lymphomas (ISCL) and the Cutaneous Lymphoma Task Force of the European Organization of Research and Treatment of Cancer (EORTC). Blood 2007; 110: 479-484. Go to original source... Go to PubMed...
    9. Senff NJ, Noordijk EM, Kim YH, et al. European Organization for Research and Treatment of Cancer and International Society for Cutaneous Lymphoma consensus recommendations for the management of cutaneous B-cell lymphomas. Blood 2008; 112: 1600-1609. Go to original source... Go to PubMed...
    10. Olsen EA, Whittaker S, Kim YH, et al. Clinical endpoints and response criteria in mycosis fungoides and Se'zary syndrome: a consensus statement of the International Society for Cutaneous Lymphomas (ISCL), the United States Cutaneous Lymphoma Consortium (USCLC), and the Cutaneous Lymphoma Task Force of the European Organization of Research and Treatment of Cancer (EORTC). J Clin Oncol 2011; 29: 2598-2607. Go to original source... Go to PubMed...
    11. Olsen EA, Vonderheid E, Pimpinelli N, et al. Revisions of the staging and classification of mycosis fungoides and Sézary syndrome: a proposal of the International Society for Cutaneous Lymphomas (ISCL) and the cutaneous Lymphoma Task Force of the European Organization of Research and Treatment of Cancer (EORTC). Blood 2007; 110: 1713-1722. Go to original source... Go to PubMed...
    12. Benton EC, Crichton S, Talpur R, et al. A cutaneous lymphoma international prognostic index (CLIPi) for mycosis fungoides and Sezary syndrome. European Journal of Cancer 2013; 49: 2859-2868. Go to original source... Go to PubMed...
    13. Mian M, Marcheselli L, Luminari S, et al. CLIPI: a new prognostic index for indolent cutaneous B cell lymphoma proposed by the International Extranodal Lymphoma Study Group (IELSG 11). Ann Hematol 2011; 90: 401-408. Go to original source... Go to PubMed...
    14. Wilcox RA. Cutaneous T-cell lymphoma: 2016 update on diagnosis, risk-stratification, and management. Am J Hematol. 2016; 91(1): 151-165. Go to original source... Go to PubMed...
    15. Kempf W, Mitteldorf C. Pathologic Diagnosis of Cutaneous Lymphomas. Dermatol Clin 2015; 33: 655-651. Go to original source... Go to PubMed...
    16. Hughes CF, Khot A, McCormack C, et al. Lack of durable disease control with chemotherapy for mycosis fungoides and Sézary syndrome: A comparative study of systemic therapy. Blood 2015; 125: 71-81. Go to original source... Go to PubMed...
    17. Tyler KH, Haverkos BM, Hastings J, et al. The role of an integrated multidisciplinary clinic in themanagement of patients with cutaneous lymphoma. Front. Oncol. 2015; 5(136): 1-5. Go to original source...
    18. Alberti-Violetti S, Talpur R, Schlichte M, et al. Advanced-Stage Mycosis Fungoides and Sézary Syndrome: Survival and Response to Treatment. Clin Lymphoma Myeloma Leuk. 2015; 15(6): e105-112. Go to original source... Go to PubMed...
    19. Duvic M. Choosing a systemic treatment for advanced stage cutaneous T-cell lymphoma: mycosis fungoides and Sézary syndrome. Hematology 2015: 529-544. Go to original source... Go to PubMed...
    20. Prince HM, Whittaker S, Hoppe RT. How I treat mycosis fungoides and Sézary syndrome. Blood 2009; 114: 4337-4353. Go to original source... Go to PubMed...

    Return to the content


    Oncology

    Madam, Sir,
    please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
    Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

    I declare:

    1. that I have met the above instruction
    2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited

    No
    Yes

    If your statement is not true, please be aware
    that brings the risk of danger to their health or the health of others.